IMPACT OF ABNORMAL 2ND-TRIMESTER MATERNAL SERUM SINGLE, DOUBLE, AND TRIPLE SCREENING ON PATIENT CHOICES ABOUT PRENATAL-DIAGNOSIS

被引：7

作者：

LOWRY, DLB

CAMPBELL, SA

KRIVCHENIA, EL

DVORIN, E

DUQUETTE, D

EVANS, MI

机构：

[1] Division of Reproductive Genetics, Departments of Obstetrics and Gynecology, Molecular Medicine, and Genetics and Pathology, Hutzel Hospital/Wayne State University School of Medicine, Corning/Metpath, Inc., Detroit, Auburn Hills, MI

来源：

FETAL DIAGNOSIS AND THERAPY | 1995年 / 10卷 / 05期

关键词：

ANEUPLOIDY; ALPHA-FETOPROTEIN; MULTIPLE-MARKER BIOCHEMICAL; SCREENING;

D O I：

10.1159/000264245

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The development of multiple-marker biochemical screening has increased the percentage of aneuploidies detected for all age groups and has also increased the abnormality/amniocentesis ratio from about 1 in 85 for maternal serum alpha-fetoprotein alone (single screening) to about 1 in 50 for either maternal serum alpha-fetoprotein plus human chorionic gonadotropin (double screening) or maternal serum alpha-fetoprotein combined with human chorionic gonadotropin and unconjugated estriol (triple screening). We evaluated the decisions to have or decline amniocentesis of 985 patients 'at risk' by either single, double, or triple screening, as multiple markers were phased in over a 3-year period. The patient acceptance of the procedure did not change (approximately 80%) either by actual risk or type of biochemical screening. The labeling of 'at risk' status is more important than actual numerical risks, and the patient perception of risk status must be considered in counseling.

引用

页码：286 / 289

页数：4

共 12 条

[1]

Merkatz I.R., Nitowsky H.M., Maori J.N., Johnston W.E., An association between low maternal serum alpha fetoprotein and fetal chromosome abnormalities, Am J Obstet Gynecol, 148, pp. 886-894, (1984)

[2]

Wald N.J., Cuckle H.S., Densem J.W., Nanchahal K., Royston P., Chard T., Maternal serum screening for Down's syndrome in early pregnancy, BMJ, 297, pp. 883-887, (1988)

[3]

Bogart M.H., Pandian M.R., Jones O.W., Abnormal maternal serum chorionic gonadotrophin levels in pregnancies with fetal chromosomal abnormalities, Prenat Diagn, 7, pp. 623-630, (1987)

[4]

Canick J.A., Knight G.J., Palomaki G.E., Haddow J.E., Cuckle H.S., Wald N.J., Low second trimester serum unconjugated oestriol in pregnancies with Down's syndrome, Br J Obstet Gynaecol, 95, pp. 330-333, (1988)

[5]

Cheng E.Y., Luthy D.A., Zebelman A.M., Williams M.A., Lieppman R.E., Hickok D.E., A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG and unconjugated estriol, Obstet Gynecol, 81, pp. 72-77, (1993)

[6]

Crossley J.A., Aitken D.A., Connor J.M., Prenatal screening for chromosomal abnormalities using maternal serum chorionic gonadotrophin, alpha-fetoprotein and age, Prenat Diagn, 11, pp. 83-101, (1991)

[7]

Wald N.J., Cuckle H.S., Densem J.W., Et al., Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome, Br J Obstet Gynaecol, 95, pp. 334-341, (1988)

[8]

Haddow J.E., Palomaki G.E., Knight G.J., Et al., Prenatal screening for Down's syndrome with the use of maternal scrum markers, N Engl J Med, 327, pp. 588-593, (1992)

[9]

Evans M.I., Dvorin E., O'Brien J.E., Moody J.L., Drugan A., Alpha-fetoprotein and biochemical screening, Reproductive Risks and Prenatal Diagnosis, pp. 223-237, (1992)

[10]

Evans M.I., Bottoms S.F., Carducci T., Et al., Determinants of altered anxiety following abnormal maternal serum alpha-fetoprotein screening, Am J Obstet Gynecol, 159, pp. 1501-1504, (1988)

← 1 2 →